Reduced-antigen, combined diphtheria, tetanus, and acellular pertussis vaccine, adsorbed (boostrix(®)): a guide to its use as a single-dose booster immunization against pertussis (Q38074886)

From Wikidata

Jump to navigation Jump to search

scientific article published on February 2013

Language	Label	Description	Also known as
English	Reduced-antigen, combined diphtheria, tetanus, and acellular pertussis vaccine, adsorbed (boostrix(®)): a guide to its use as a single-dose booster immunization against pertussis	scientific article published on February 2013

Statements

scholarly article

1 reference

Europe PubMed Central

28 August 2017

1 reference

Europe PubMed Central

Reduced-antigen, combined diphtheria, tetanus, and acellular pertussis vaccine, adsorbed (boostrix(®)): a guide to its use as a single-dose booster immunization against pertussis (English)

1 reference

Europe PubMed Central

28 August 2017

pertussis vaccine

1 reference

based on heuristic

inferred from title

1

object named as

Lesley J Scott

1 reference

Europe PubMed Central

28 August 2017

author name string

Paul L McCormack

2

1 reference

Europe PubMed Central

28 August 2017

publication date

1 February 2013

1 reference

Europe PubMed Central

28 August 2017

1 reference

Europe PubMed Central

28 August 2017

27

1 reference

Europe PubMed Central

28 August 2017

1

1 reference

Europe PubMed Central

28 August 2017

75-81

1 reference

Europe PubMed Central

28 August 2017

https://scigraph.springernature.com/pub.10.1007/s40259-012-0009-y

0 references

Immune responses in adults to revaccination with a tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine 10 years after a previous dose

1 reference

https://api.crossref.org/works/10.1007%2FS40259-012-0009-Y

21 January 2018

Reduced-antigen, combined diphtheria, tetanus and acellular pertussis vaccine, adsorbed (Boostrix®): a review of its properties and use as a single-dose booster immunization

1 reference

https://api.crossref.org/works/10.1007%2FS40259-012-0009-Y

21 January 2018

Immunogenicity and reactogenicity of a reduced-antigen-content diphtheria-tetanus-acellular pertussis vaccine in healthy Taiwanese children and adolescents

1 reference

https://api.crossref.org/works/10.1007%2FS40259-012-0009-Y

21 January 2018

Reactogenicity and immunogenicity of reduced antigen content diphtheria-tetanus-acellular pertussis vaccine (dTpa) administered as a booster to 4-6 year-old children primed with four doses of whole-cell pertussis vaccine

1 reference

https://api.crossref.org/works/10.1007%2FS40259-012-0009-Y

21 January 2018

Effects of lowering the aluminium content of a dTpa vaccine on its immunogenicity and reactogenicity when given as a booster to adolescents

1 reference

https://api.crossref.org/works/10.1007%2FS40259-012-0009-Y

21 January 2018

A decennial booster dose of reduced antigen content diphtheria, tetanus, acellular pertussis vaccine (Boostrix™) is immunogenic and well tolerated in adults

1 reference

https://api.crossref.org/works/10.1007%2FS40259-012-0009-Y

21 January 2018

Decennial administration of a reduced antigen content diphtheria and tetanus toxoids and acellular pertussis vaccine in young adults

1 reference

https://api.crossref.org/works/10.1007%2FS40259-012-0009-Y

21 January 2018

Immunogenicity and safety of a tetanus toxoid, reduced diphtheria toxoid and three-component acellular pertussis vaccine in adults 19-64 years of age.

1 reference

https://api.crossref.org/works/10.1007%2FS40259-012-0009-Y

21 January 2018

Vaccination of adults 65 years of age and older with tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Boostrix(®)): results of two randomized trials

1 reference

https://api.crossref.org/works/10.1007%2FS40259-012-0009-Y

21 January 2018

Efficacy of acellular pertussis vaccine in early childhood after household exposure.

1 reference

https://api.crossref.org/works/10.1007%2FS40259-012-0009-Y

21 January 2018

Clinical experience of a tricomponent acellular pertussis vaccine combined with diphtheria and tetanus toxoids for primary vaccination in 22,505 infants

1 reference

https://api.crossref.org/works/10.1007%2FS40259-012-0009-Y

21 January 2018

Persistence of antibodies 3 years after booster vaccination of adults with combined acellular pertussis, diphtheria and tetanus toxoids vaccine.

1 reference

https://api.crossref.org/works/10.1007%2FS40259-012-0009-Y

21 January 2018

High levels of antibody in adults three years after vaccination with a reduced antigen content diphtheria-tetanus-acellular pertussis vaccine.

1 reference

https://api.crossref.org/works/10.1007%2FS40259-012-0009-Y

21 January 2018

Booster vaccination of adults with reduced-antigen-content diphtheria, Tetanus and pertussis vaccine: immunogenicity 5 years post-vaccination.

1 reference

https://api.crossref.org/works/10.1007%2FS40259-012-0009-Y

21 January 2018

Pertussis vaccine effectiveness after mass immunization of high school students in Australia.

1 reference

https://api.crossref.org/works/10.1007%2FS40259-012-0009-Y

21 January 2018

Efficacy of an acellular pertussis vaccine among adolescents and adults.

1 reference

https://api.crossref.org/works/10.1007%2FS40259-012-0009-Y

21 January 2018

Effectiveness of adolescent and adult tetanus, reduced-dose diphtheria, and acellular pertussis vaccine against pertussis.

1 reference

https://api.crossref.org/works/10.1007%2FS40259-012-0009-Y

21 January 2018

Reduced-antigen-content-diphtheria-tetanus-acellular-pertussis and inactivated polio vaccine as a booster for adolescents 10 to 14 years of age.

1 reference

https://api.crossref.org/works/10.1007%2FS40259-012-0009-Y

21 January 2018

Immunogenicity and reactogenicity of co-administered tetanus-diphtheria-acellular pertussis (Tdap) and tetravalent meningococcal conjugate (MCV4) vaccines compared to their separate administration

1 reference

https://api.crossref.org/works/10.1007%2FS40259-012-0009-Y

21 January 2018

Safety and immunogenicity of a tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine when co-administered with influenza vaccine in adults.

1 reference

https://api.crossref.org/works/10.1007%2FS40259-012-0009-Y

21 January 2018

Post-marketing safety evaluation of a tetanus toxoid, reduced diphtheria toxoid and 3-component acellular pertussis vaccine administered to a cohort of adolescents in a United States health maintenance organization

1 reference

https://api.crossref.org/works/10.1007%2FS40259-012-0009-Y

21 January 2018

An assessment of the safety of adolescent and adult tetanus-diphtheria-acellular pertussis (Tdap) vaccine, using active surveillance for adverse events in the Vaccine Safety Datalink

1 reference

https://api.crossref.org/works/10.1007%2FS40259-012-0009-Y

21 January 2018

Identifiers

10.1007/S40259-012-0009-Y

1 reference

Europe PubMed Central

28 August 2017

1 reference

Europe PubMed Central

28 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38074886&oldid=2144859309"